-
Je něco špatně v tomto záznamu ?
Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study
P. Rajwa, D. Robesti, M. Chaloupka, F. Zattoni, A. Giesen, NA. Huebner, A. Krzywon, M. Miszczyk, M. Moll, R. Stando, E. Cisero, S. Semko, E. Checcucci, G. Devos, M. Apfelbeck, C. Gatti, G. Marra, RCN. van den Bergh, G. Goldner, S. Rasul, F. Ceci,...
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, multicentrická studie
- MeSH
- antigeny povrchové metabolismus MeSH
- cytoredukční chirurgie MeSH
- glutamátkarboxypeptidasa II metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů MeSH
- nádory prostaty * patologie chirurgie MeSH
- pozitronová emisní tomografie * metody MeSH
- prostatektomie * metody MeSH
- prostatický specifický antigen krev MeSH
- retrospektivní studie MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: De novo oligometastatic prostate cancer (omPCa) on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is a new disease entity and its optimal management remains unknown. OBJECTIVE: To analyze the outcomes of patients treated with cytoreductive radical prostatectomy (cRP) for omPCa on PSMA-PET. DESIGN, SETTING, AND PARTICIPANTS: Overall, 116 patients treated with cRP at 13 European centers were identified. Oligometastatic PCa was defined as miM1a and/or miM1b with five or fewer osseous metastases and/or miM1c with three or fewer lung lesions on PSMA-PET. INTERVENTION: Cytoreductive radical prostatectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Thirty-day complications according to Clavien-Dindo, continence rates, time to castration-resistant PCa (CRPC), and overall survival (OS) were analyzed. RESULTS AND LIMITATIONS: Overall, 95 (82%) patients had miM1b, 18 (16%) miM1a, and three (2.6%) miM1c omPCa. The median prebiopsy prostate-specific antigen was 14 ng/ml, and 102 (88%) men had biopsy grade group ≥3 PCa. The median number of metastases on PSMA-PET was 2; 38 (33%), 29 (25%), and 49 (42%) patients had one, two, and three or more distant positive lesions. A total of 70 (60%) men received neoadjuvant systemic therapy, and 37 (32%) underwent metastasis-directed therapy. Any and Clavien-Dindo grade ≥3 complications occurred in 36 (31%) and six (5%) patients, respectively. At a median follow-up of 27 mo, 19 (16%) patients developed CRPC and eight (7%) patients died. The 1-yr urinary continence rate was 82%. The 2-yr CRPC-free survival and OS were 85.8% (95% confidence interval [CI] 78.5-93.7%) and 98.9% (95% CI 96.8-100%), respectively. The limitations include retrospective design and short-term follow-up. CONCLUSIONS: Cytoreductive radical prostatectomy is a safe and feasible treatment option in patients with de novo omPCa on PSMA-PET. Despite overall favorable oncologic outcomes, some of these patients have a non-negligible risk of early progression and thus should be considered for multimodal therapy. PATIENT SUMMARY: We found that patients treated at expert centers with surgery for prostate cancer, with a limited number of metastases detected using novel molecular imaging, have favorable short-term survival, functional results, and acceptable rates of complications.
Department of Radiotherapy Holy Cross Cancer Center Kielce Poland
Department of Surgery Candiolo Cancer Institute FPO IRCCS Candiolo Turin Italy
Department of Surgery Oncology and Gastroenterology University of Padua Padua Italy
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Città della Salute e della Scienza University of Turin Turin Italy
Department of Urology LMU Klinikum Ludwig Maximilians University Munich Munich Germany
Department of Urology Medical University of Silesia Zabrze Poland
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology Skåne University Hospital Lund University Malmö Sweden
Department of Urology St Antonius Hospital Utrecht The Netherlands
Department of Urology University Hospitals Leuven Leuven Belgium
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Nuclear Medicine IEO European Institute of Oncology IRCCS Milan Italy
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019635
- 003
- CZ-PrNML
- 005
- 20241024110707.0
- 007
- ta
- 008
- 241015s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euo.2023.09.006 $2 doi
- 035 __
- $a (PubMed)37845121
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland
- 245 10
- $a Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study / $c P. Rajwa, D. Robesti, M. Chaloupka, F. Zattoni, A. Giesen, NA. Huebner, A. Krzywon, M. Miszczyk, M. Moll, R. Stando, E. Cisero, S. Semko, E. Checcucci, G. Devos, M. Apfelbeck, C. Gatti, G. Marra, RCN. van den Bergh, G. Goldner, S. Rasul, F. Ceci, F. Dal Moro, F. Porpiglia, P. Gontero, A. Bjartell, C. Stief, A. Heidenreich, S. Joniau, A. Briganti, SF. Shariat, G. Gandaglia, EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party
- 520 9_
- $a BACKGROUND: De novo oligometastatic prostate cancer (omPCa) on prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is a new disease entity and its optimal management remains unknown. OBJECTIVE: To analyze the outcomes of patients treated with cytoreductive radical prostatectomy (cRP) for omPCa on PSMA-PET. DESIGN, SETTING, AND PARTICIPANTS: Overall, 116 patients treated with cRP at 13 European centers were identified. Oligometastatic PCa was defined as miM1a and/or miM1b with five or fewer osseous metastases and/or miM1c with three or fewer lung lesions on PSMA-PET. INTERVENTION: Cytoreductive radical prostatectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Thirty-day complications according to Clavien-Dindo, continence rates, time to castration-resistant PCa (CRPC), and overall survival (OS) were analyzed. RESULTS AND LIMITATIONS: Overall, 95 (82%) patients had miM1b, 18 (16%) miM1a, and three (2.6%) miM1c omPCa. The median prebiopsy prostate-specific antigen was 14 ng/ml, and 102 (88%) men had biopsy grade group ≥3 PCa. The median number of metastases on PSMA-PET was 2; 38 (33%), 29 (25%), and 49 (42%) patients had one, two, and three or more distant positive lesions. A total of 70 (60%) men received neoadjuvant systemic therapy, and 37 (32%) underwent metastasis-directed therapy. Any and Clavien-Dindo grade ≥3 complications occurred in 36 (31%) and six (5%) patients, respectively. At a median follow-up of 27 mo, 19 (16%) patients developed CRPC and eight (7%) patients died. The 1-yr urinary continence rate was 82%. The 2-yr CRPC-free survival and OS were 85.8% (95% confidence interval [CI] 78.5-93.7%) and 98.9% (95% CI 96.8-100%), respectively. The limitations include retrospective design and short-term follow-up. CONCLUSIONS: Cytoreductive radical prostatectomy is a safe and feasible treatment option in patients with de novo omPCa on PSMA-PET. Despite overall favorable oncologic outcomes, some of these patients have a non-negligible risk of early progression and thus should be considered for multimodal therapy. PATIENT SUMMARY: We found that patients treated at expert centers with surgery for prostate cancer, with a limited number of metastases detected using novel molecular imaging, have favorable short-term survival, functional results, and acceptable rates of complications.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a prostatektomie $x metody $7 D011468
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a nádory prostaty $x patologie $x chirurgie $7 D011471
- 650 12
- $a pozitronová emisní tomografie $x metody $7 D049268
- 650 _2
- $a cytoredukční chirurgie $7 D065426
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a prostatický specifický antigen $x krev $7 D017430
- 650 _2
- $a glutamátkarboxypeptidasa II $x metabolismus $7 D043425
- 650 _2
- $a antigeny povrchové $x metabolismus $7 D000954
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Robesti, Daniele $u Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Chaloupka, Michael $u Department of Urology, LMU Klinikum, Ludwig-Maximilians University Munich, Munich, Germany
- 700 1_
- $a Zattoni, Fabio $u Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
- 700 1_
- $a Giesen, Alexander $u Department of Urology, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Huebner, Nicolai A $u Department of Urology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Krzywon, Aleksandra $u Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
- 700 1_
- $a Miszczyk, Marcin $u IIIrd Department of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland
- 700 1_
- $a Moll, Matthias $u Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Stando, Rafał $u Department of Radiotherapy, Holy Cross Cancer Center, Kielce, Poland
- 700 1_
- $a Cisero, Edoardo $u Division of Urology, Department of Oncology, School of Medicine, University of Turin, San Luigi Hospital, Orbassano, Italy
- 700 1_
- $a Semko, Sofiya $u Department of Urology, Faculty of Medicine, University Hospital Cologne, University Cologne, Cologne, Germany
- 700 1_
- $a Checcucci, Enrico $u Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy
- 700 1_
- $a Devos, Gaëtan $u Department of Urology, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Apfelbeck, Maria $u Department of Urology, LMU Klinikum, Ludwig-Maximilians University Munich, Munich, Germany
- 700 1_
- $a Gatti, Cecilia $u Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy
- 700 1_
- $a Marra, Giancarlo $u Department of Urology, Città della Salute e della Scienza, University of Turin, Turin, Italy
- 700 1_
- $a van den Bergh, Roderick C N $u Department of Urology, St Antonius Hospital, Utrecht, The Netherlands
- 700 1_
- $a Goldner, Gregor $u Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Rasul, Sazan $u Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Ceci, Francesco $u Division of Nuclear Medicine, IEO European Institute of Oncology, IRCCS, Milan, Italy
- 700 1_
- $a Dal Moro, Fabrizio $u Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
- 700 1_
- $a Porpiglia, Francesco $u Division of Urology, Department of Oncology, School of Medicine, University of Turin, San Luigi Hospital, Orbassano, Italy
- 700 1_
- $a Gontero, Paolo $u Department of Urology, Città della Salute e della Scienza, University of Turin, Turin, Italy
- 700 1_
- $a Bjartell, Anders $u Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden
- 700 1_
- $a Stief, Christian $u Department of Urology, LMU Klinikum, Ludwig-Maximilians University Munich, Munich, Germany
- 700 1_
- $a Heidenreich, Axel $u Department of Urology, Faculty of Medicine, University Hospital Cologne, University Cologne, Cologne, Germany
- 700 1_
- $a Joniau, Steven $u Department of Urology, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Briganti, Alberto $u Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Division of Urology, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA. Electronic address: shahrokh.shariat@meduniwien.ac.at
- 700 1_
- $a Gandaglia, Giorgio $u Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
- 710 2_
- $a EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party
- 773 0_
- $w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 7, č. 4 (2024), s. 721-734
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37845121 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110701 $b ABA008
- 999 __
- $a ok $b bmc $g 2202087 $s 1231608
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 7 $c 4 $d 721-734 $e 20231014 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
- LZP __
- $a Pubmed-20241015
